SCHEMBL1128142

SCHEMBL1128142

CCOC(=O)c1c(O)n2ccccc2c(Cc2cc(F)cc(F)c2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.46
ALDH1A1 P00352 9/20 0.46
HPGD P15428 5/20 0.46
GAA P10253 4/20 0.46
GLA P06280 2/20 0.46
IDO1 P14902 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
MAPK1 P28482 1/20 0.44
HBB P68871 1/20 0.44
HIF1A Q16665 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 6/20 0.39
ALOX5 P09917 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127254 0.88 ALDH1A1 (0.48) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL4289628 0.88 KDM4E (0.44) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL12627624 0.86 KDM4E (0.42) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL1127429 0.84 ALDH1A1 (0.45) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1127987 0.84 ALDH1A1 (0.49) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL13658301 0.83 KDM4E (0.50) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL13658303 0.83 ALDH1A1 (0.44) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1128375 0.83 PTGES (0.48) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1127411 0.82 ALDH1A1 (0.43) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1127428 0.82 ALDH1A1 (0.45) KDM4EALDH1A1HPGDGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF KDM4E 1012/4885ALDH1A1 1614/4885HPGD 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.